2022 CSH Professor Wang Ying: A new breakthrough in CAR-T therapy, Herkirensai injection is expected to break the bottleneck of r/r B-ALL treatment

Listening to the sound of blood and perceiving the rhythm of life, the much-anticipated "17th National Hematology Academic Conference of the Chinese Medical Association" was grandly opened

Figure 1 Prognosis and recurrence of adult B-ALL in China

There is currently no uniform treatment regimen

Figure 2 Immunotherapy mechanism

Tisagenlecleucel was used in the ELIANA study to treat patients with r/r B-ALL aged 3-21 years, with an objective response rate (ORR) (CR+CRi) of 82.

Figure 3 The current approval status of CD19 CAR-T cell products

Figure 4 r/r ALL domestic and foreign guideline treatment recommendations

Figure 5 Results of pre-clinical studies of Herkirensai in adult B-ALL treatment

Among children and adolescents, 12 patients with bone marrow r/r obtained CR or CRi after a single treatment, and the ORR was 83.

Figure 6 Results of a preclinical study of Heckylendeux in the treatment of children and adolescents with B-ALL

In a Phase I clinical study of Hekylendsal in the treatment of adult r/r B-ALL, 9 patients had an ORR of 88.
9%
within 3 months.

Registered Phase II clinical trials of R/R B-ALL in adults are currently underway and the data are robust
.

Figure 7 Results of Phase I clinical studies in Herkilens

Figure 8 Herkirensai Phase II clinical trial design

In view of the results of a large number of clinical studies, Herkirensai's new drug marketing application for adult r/r B-ALL indications is actively being prepared, and at the same time, the registered clinical study in children and adolescents (3-18 years old) r/r B-ALL patients has also obtained the clinical trial implied permission of the Drug Evaluation Center of the State Drug Administration on August 19, 2022, and the clinical trial is ongoing
.

It is believed that after the approval of the Hekylon Race for marketing, it will be able to fill the gap of targeted CD19 CAR-T treatment r/r B-ALL in China and bring hope
to more patients.
Professor Wang Jianxiang concluded
that Professor Wang Ying shared in detail the research status of r/r B-ALL therapy, the application of CAR-T therapy in r/r B-ALL, and the application of Heqirensai, the first Chinese targeted CD19 CAR-T therapy drug in R/r B-ALL
.

According to the relevant research and clinical cases of Hekylon race shared by Professor Wang Ying, we are full of confidence in the future clinical application of Hekylon race in r/r B-ALL! Editor: Su Meng Typesetting: Wenting Execution: Wenting

Poke "Read the original article" to see more